Product Information
TRI-VYLIBRA 28 TABLET is a generic product labeled by Afaxys Pharma, LLC, priced at $0.1268 per EA under NDC 50102023311. Its NADAC has been published 433 times since May 9, 2018.
FDA first approved this application on Jul 6, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Afaxys Pharma, LLCNDC
50102023311
Classification
Generic
Dosage Form
KIT
Effective Date
8/19/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205441FDA Approved
7/6/2016
TE Code
AB
On Market Since
7/6/2016
Price Statistics
The NADAC for TRI-VYLIBRA 28 TABLET has been published 433 times since May 9, 2018, and over the history we have for it it has declined 46.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1268 per EA |
|---|---|
| All-time high | $0.2397 (Sep 12, 2018) |
| All-time low | $0.1072 (Jul 17, 2024) |
| 52-week high | $0.1375 |
| 52-week low | $0.1259 |
| Median price | $0.1559 |
| Average price | $0.1644 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 433 |
| Tracking since | May 9, 2018 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 15% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TRI-VYLIBRA 28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-VYLIBRA 28 TABLET, manufactured by Afaxys Pharma, LLC, is $0.1268 per EA (NDC 50102023311), effective Aug 19, 2026.
How has the price of TRI-VYLIBRA 28 TABLET changed over time?
Over the history we have for it, the NADAC for TRI-VYLIBRA 28 TABLET has declined 46.5%. It has been tracked across 433 weekly CMS publications since May 9, 2018.
What are the highest and lowest recorded NADAC prices for TRI-VYLIBRA 28 TABLET?
Since May 9, 2018, the NADAC for TRI-VYLIBRA 28 TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.2397 (Sep 12, 2018), with a median of $0.1559 per EA.
Are there cheaper alternatives to TRI-VYLIBRA 28 TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRI-VYLIBRA LO TABLET, is $0.1083 per EA — about 15% below TRI-VYLIBRA 28 TABLET.
Who manufactures TRI-VYLIBRA 28 TABLET?
TRI-VYLIBRA 28 TABLET (NDC 50102023311) is labeled by Afaxys Pharma, LLC, and CMS classifies it as a generic product.